Home » Authors » Nuala Moran

Articles by Nuala Moran

Arakis Providing Exit Via £106.5M Sosei Acquisition

July 20, 2005

LONDON - Sosei Co Ltd. is taking over Arakis Ltd. for £106.5 million (US$187.4 million) in a cash-and-shares deal that creates an Anglo-Japanese company valued at £278 million. (BioWorld International)

Arakis Providing Exit Via £106.5M Sosei Acquisition

July 20, 2005

Xention's Third Round Gets £11M For Ion Channel Drugs

July 20, 2005

Veteran Stem Cell Company Raises £6M On London's AIM

July 20, 2005

Xention's Third Round Gets £11M For Ion Channel Drugs

July 20, 2005

Arakis Providing Exit Via £106.5M Sosei Acquisition

July 20, 2005

LONDON - Sosei Co Ltd. is taking over Arakis Ltd. for £106.5 million (US$187.4 million) in a cash-and-shares deal that creates an Anglo-Japanese company valued at £278 million. (BioWorld International)

Arakis Providing Exit Via £106.5M Sosei Acquisition

July 20, 2005

ReNeuron Plans IPO, Enters Agreement With StemCells Inc.

July 13, 2005

Alizyme Aligned With FDA For Renzapride Pivotal Trial

July 13, 2005

SR Pharma Buying Atugen For £6.2M, Raising Money

July 13, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...